I-Mab Announces First Patient Dosed in Phase 1/2a Clinical Trial of Anti-CD47 Antibody, TJC4, in China

NEXT STORY
La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Named Patient Emergency Use in Patients with Septic Shock Due to COVID-19 at Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom
PREV STORY
Biomerica Signs Two Definitive Agreements with Mount Sinai Medical School in New York to Scale-up a Laboratory Version Serological Test for COVID-19 That Enables High-Volume Screenings in Labs
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

BioXcel Therapeutics Announces Compassionate Use Program at Massachusetts General Hospital for BXCL501 to Treat COVID-19 Patients Suffering from Delirium and Agitation

author_avatar
NASDAQ Market News

BriaCell Announces Investor and Media Outreach Programs

author_avatar
NASDAQ Market News

FIT Biotech Oy: FIT Biotech Receives EUR 644,868 Payment from European HIV Vaccine Alliance (EHVA)

FIT Biotech Oy  Company release 12 July, 2017 at 4:00 PM EET FIT Biotech ...

author_avatar
NASDAQ Market News